MYCN Reprograms Neuroblastoma Metabolism
Abstract
Despite current aggressive regimens, the majority of patients with MYCN amplification die due to drug-resistant disease, and further intensification of chemotherapy will not significantly improve this outcome. We propose an entirely novel strategy to oppose MYCN oncogenic function in NB: by blocking the metabolic reprogramming driven by MYCN. Our guiding hypothesis is that lipid metabolism is required for NB tumorigenesis. We have shown that lipid metabolism is a selective metabolic dependency of MYCN-induced tumors. Targeting MYCN-driven lipogenesis effectively blocks in vivo tumor growth in multiple models of NB and sensitize NB tumors to conventional chemotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1158153
Entities
People
- Cristian Coarfa
- Eveline Barbieri
- Ling Tao
- Mirthala Moreno Smith
Organizations
- Baylor College of Medicine